Abstract This investigation aimed to assess whether inhibition of cathecol-O-methyl transferase (COMT) by tolcapone could provide neuroprotection against HIV-associated neurodegenerative effects. This study was conducted based on a previous work, which showed that a single nucleotide polymorphism (SNP) at position 158 (val158met) in COMT, resulted in 40 % lower COMT activity. Importantly, this reduction confers a protective effect against HIV-associated neurocognitive disorders (HAND), which have been linked to HIV-associated brain changes. SH-SY5Y-differentiated neurons were exposed to macrophage-propagated HIV (neurotropic MACS2-Br strain) in the presence or absence of tolcapone for 6 days. RNA was extracted, and qPCR was performed using Qiagen RT2 custom array consisting of genes for neuronal and synaptic integrity, COMT and proinflammatory markers. Immunofluorescence was conducted to validate the gene expression changes at the protein level. Our findings demonstrated that HIV significantly increased the messenger RNA (mRNA) expression of COMT while reducing the expression of microtubule-associated protein 2 (MAP2) (p=0.0015) and synaptophysin (SYP) (p=0.012) compared to control. A concomitant exposure of tolcapone ameliorated the perturbed expression of MAP2 (p=0.009) and COMT (p=0.024) associated with HIV. Immunofluorescence revealed a trend reduction of SYP and MAP2 with exposure to HIV and that concomitant exposure of tolcapone increased SYP (p= 0.016) compared to HIV alone. Our findings demonstrated in vitro that inhibition of COMT can ameliorate HIVassociated neurodegenerative changes that resulted in the decreased expression of the structural and synaptic components MAP2 and SYP. As HIV-associated dendritic and synaptic damage are contributors to HAND, inhibition of COMT may represent a potential strategy for attenuating or preventing some of the symptoms of HAND.
Introduction
Cognitive impairment remains prevalent among individuals living with HIV despite the effectiveness of combination antiretroviral therapy (cART) in reducing systemic viral burden.
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Although antiretrovirals (ARVs) suppress HIV-1 RNA levels, detectable cerebrospinal fluid (CSF) viral load still persists in some patients (Garvey et al. 2009; Mellgren et al. 2005; Spudich et al. 2005; van Lelyveld et al. 2010) . While some evidence suggests that ARVs could potentially improve cognitive performance (Guevara-Silva 2014), others have found deterioration of cognitive function (Kaul 2009; Marra et al. 2009 ). These inconsistencies have been attributed to the varying degrees of drug toxicity and blood-brain barrier (BBB) penetrance (Marra et al. 2009; Rawson et al. 2012) . However, neurobiological heterogeneity, particularly in biological pathways relevant to cognition, is also likely to explain the current inconsistencies in the literature.
On such pathway is dopamine biosynthesis and regulation, which play an essential role in modulating prefrontal cortex (PFC) cognitive functions, especially high-level executive functioning (Gupta et al. 2011; Tunbridge et al. 2006 ). Goldman-Rakic et al. (Goldman-Rakic et al. 2000) described an inverted U-shaped relationship between levels of cortical dopamine/dopamine (D1) receptors activation and PFC cognitive performance. An intermediate level of cortical dopamine was described as being optimal; with sub-or supraoptimal levels of dopamine causing a decrease in PFCassociated cognitive performance. Thus, mechanisms involved in regulating levels of dopamine within synapses are of particular importance.
One of the main enzymes responsible for the degradation of dopamine is cathecol-O-methyl transferase (COMT). COMT is responsible for the majority of dopamine degradation in the PFC due to the low expression of dopamine transporter (DAT) in this region, which has 1000-fold higher affinity for dopamine and is responsible for the clearing of dopamine from synapses in other brain regions (Lewis et al. 2001 ). Of particular interest, a functional polymorphism of COMT involving a substitution of valine (Val) with methionine (Met) at codon 158 for membrane-bound COMT (equivalent to codon 108 for soluble COMT) has been associated with 40 % lower COMT activity and enhanced PFC-related cognitive performance among individuals with Met/Met compared to Val/Val genotype (Chen et al. 2004; Egan et al. 2001) . Several studies have supported these initial findings in healthy individuals, showing that Met/Met genotype carriers perform better than individuals with Val/Val in various PFC-related functional tasks, including the Wisconsin Card Sorting Test and multi-source interference task (Barnett et al. 2007; Egan et al. 2001; Shehzad et al. 2012) . However, recent work suggests that this relationship is context dependent. Among individuals with HIV, Met/Met carriers were found to have better cognitive function compared to Val/Val carriers, similar to that observed in healthy controls; however, in the presence of methamphetamine use, the protective effect of Met/Met was attenuated, presumably due to supra-optimal levels of extracellular dopamine (Bousman et al. 2010) .
The difference in COMT enzymatic activity has also been replicated in an animal model of COMT Val158Met, where cognitive deficit was observed using T-maze (working memory task) in mice with Val/Val alleles (Risbrough et al. 2014) . Interestingly, treatment with tolcapone, a central nervous system (CNS) penetrant COMT inhibitor that is approved for the treatment of Parkinson's disease (Marsala et al. 2012) , significantly reversed the deficits observed in Val/Val mice (Risbrough et al. 2014) . Various studies have also reported a genotype-dependent effect of tolcapone where cognitive performance was improved in Val/Val but not Met/Met individuals, further strengthening the notion of the inverted U-shaped relation of the optimal dopamine level and cognitive performance (Apud et al. 2007; Bitsios and Roussos 2011; Farrell et al. 2012) .
Previously, we have also shown at the cellular level that individuals with HIV-associated neurocognitive disorder (HAND) have synaptic and dendritic loss in the frontal cortex (Everall et al. 1991 (Everall et al. , 1993 (Everall et al. , 1999 . This has further been characterised by our findings of a loss of calbindin interneurons in layers II and III of the frontal cortex of individuals with HAND (Chana et al. 2006; Masliah et al. 1995) . Masliah et al. (Masliah et al. 1997 ) also reported a strong relationship between the severity of HIV-associated neurocognitive impairment and neurodegeneration, as quantified by immunohistochemistry signal of microtubule-associated protein 2 (MAP2). This neuronal and synaptic loss is believed to have contributed to cerebral atrophy in individuals living with HIV, leading to the disruption of connectivity that may play a significant role in cognitive impairment (Steinbrink et al. 2013) .
The current study aimed to investigate the effect of decreasing COMT activity on HIV-associated neurotoxicity. Based on past evidence, we hypothesised that inhibiting COMT activity using tolcapone would have a protective effect against HIVassociated neurotoxicity. (Agholme et al. 2010; Encinas et al. 2000) .
Methods

SH-SY5Y neuronal model
Macrophages cultures
Peripheral blood mononuclear cells (PBMCs) were purified from buffy coat from four donors (Australian Red Cross Blood Service, Australia) by Histopaque (Sigma, USA) density gradient centrifugation. Monocytes were isolated from PBMCs by plastic adherence. Following 2 h incubation, the culture flask with PBMCs was gently agitated and washed with Isocove's Modified Dulbecco's Medium (IMDM) (Life Technologies) with 10 % heat-inactivated FBS to isolate monocytes, which stay adhered to the flask. Monocytesderived macrophages (MDM) were cultured in IMDM with 10 % heat-inactivated human serum (Australian Red Cross Blood Service, Australia), human macrophage colonystimulating factor (M-CSF) [12.5 ng/ml] (Bio-Scientific, Australia), penicillin [100 U/ml] and Streptomycin [0.1 mg/ml]. MDM were cultured for 6 days to mature with media changed completely twice a week.
HIV culture and harvest
Mature MDMs (6 days old) were inoculated with a neurotropic HIV strain (MACS2-Br) isolated from autopsy brain of a subject who died from AIDS and had HIV-associated dementia (HAD) as well as HIV encephalitis (Gorry et al. 2001 ). MDMs were incubated at 37°C and 5 % CO 2 overnight in viral supernatant before a fresh media change. Cultures were given three quarter media changes twice weekly with harvested supernatant filtered through a 0.45-μm filter and stored at −80°C. Cultures were terminated when cytopathic effect (i.e. the presence of multinucleated giant cells) was evident in most cells. A p24 ELISA assay (Leidos Biomedical Research, USA) was used to determine the virus concentration.
Tolcapone lactase dehydrogenase toxicity assay
Tolcapone was dissolved in dimethyl sulfoxide (DMSO), and its toxicity was measured using CytoTox 96® NonRadioactive Cytotoxicity Assay (Promega, USA), which is a colometric assay measuring the extracellular lactase dehydrogenase (LDH) released by damaged cells. Various concentrations of tolcapone were assessed for toxicity including 0.01, 0.1, 1, 10 (IC 50 ) and 100 nM.
Experimental conditions
The technical triplicates of double-differentiated SH-SY5Y cells were cultured in 6-well plates for RNA extraction and quantitative real-time PCR (qRT-PCR), as well as in 12-well plates containing 16-mm coverslips to be processed for immunofluorescence. Cells were exposed to MACS2-Br HIV supernatant [500 pg/ml of p24] and tolcapone [10 nM based on IC 50 ] (Sigma, USA) or vehicle (DMSO) for 6 days as described in Table 1 .
qRT-PCR
RNA samples were extracted using Purelink RNA Minikit (Life Technologies, USA) and quality examined on 2100 Bioanalyzer Instrument (Agilent, USA), with cDNA synthesised using the RT 2 HT First Strand Kit (Qiagen, USA) and qPCR performed using RT 2 custom array (SABiosciences, Australia) with SYBR Green mastermix (SABiosciences, Australia). The arrays consisted of 32 genes, including neuronal and synaptic integrity markers, COMT and proinflammatory markers that have previously been implicated or dysregulated in HIV-associated neurodegeneration or cognitive impairment, as well as 3 reference genes (GUSB, GAPDH, PPIA) and 3 internal controls (HGDC, RTC, PPC) (Supplemental Table 1 ). The qPCR reaction mix was prepared as per manufacturer's protocol and pipetted onto the array plates using EpMotion 5070 (Eppendorf, USA) to maintain high consistency. The qPCR reaction and data collection were performed on ViiA™ 7 Real-Time PCR System (Life Technologies, USA) and exported to Microsoft Excel (Microsoft, USA) for further analysis. The raw data was formatted in Microsoft Excel (Microsoft, USA) template and uploaded to the Qiagen web-based RT 2 Profiler PCR Array Data Analysis V3.5 (SABiosciences, Australia) for fold change calculation using the arithmetic mean of the three housekeeping genes and relative to controls using 2 −ΔΔCt . Differences in fold changes between groups were assessed within the web-based software, which is powered by Student's t test.
Immunofluorescence Double-differentiated SH-SY5Y neuronal cells exposed to experimental conditions were washed quickly in phosphate buffered saline [0.1 M] (PBS) (Sigma Aldrich, USA) followed by fixation in 4 % paraformaldehyde (PFA) (Sigma Aldrich, 
Pilot study for integrated optical density acquisition
A pilot study was conducted to optimise the parameters of integrated optical density (IOD) acquisition. Slide-mounted coverslips were visualised using fluorescence microscopy. A contour defining our area of interest (AOI) was traced in StereoInvestigator 10 (MBF Biosciences, USA) to include the maximum square within the round coverslip. The fractionator probe was used to generate approximately 50 systematic random sampling (SRS) fields within the AOI. Numbers of cells were counted and monochrome images were taken across three channels (DAPI, Alexa 488, Alexa 594) for each field. Sampling fields with no cells were excluded, and sampling parameters such as exposure time, UV intensity and frame size were kept consistent across all sampling sites and conditions. The sampled images were then imported into Image-Pro Plus (Media Cybernetics, USA) where IOD measurements were carried out and data exported to Microsoft Excel (Microsoft, USA). IOD measurements were calculated based on multiplying the area (μM 2 ) by the intensity (mapped to a black and white scale where 0 = black and 255 = white). The acquisition returned with 33 fields satisfying the inclusion criteria. A correlation of 95.1 % reflects that DAPI IOD serves as a suitable parameter to correct for cell number variation in each field of interest (Supplemental Table 2 ). The cumulative mean intensity of DAPI, MAP2 as well as SYP were plotted against the number of sampling fields and revealed that 25 sampling fields were required to generate reliable IOD measurements.
Measurement of IOD
Slide-mounted coverslips were visualised using fluorescence microscopy. The acquisition of IOD measurements were carried out as optimised in the pilot study. The intensity of fluorescence signal for MAP2 and SYP were calculated as a ratio of the IOD of DAPI to account for variation in cell counts and degradation of signal across time. The corrected data was analysed using a Student's t test in IBM SPSS Statistics 21 (IBM Corp., USA).
Results
Tolcapone toxicity via LDH assay LDH assay revealed no significant toxicity in SY5Y neurons exposed to different concentrations of tolcapone [0.01-100 nM] for 30 min and 24 h (Supplemental Fig. 1) . Therefore, the concentration of 10 nM (IC 50 ) was used in the experiment.
Gene expression changes by qRT-PCR
The current study examined the messenger RNA (mRNA) expression of candidate genes (Supplemental Table 2 ) in SH-SY5Y neurons exposed to HIV and/or tolcapone. All RNA samples have RNA integrity numbers (RIN) of 9.6 and above. A one-way ANOVA comparison between groups revealed no difference in the arithmetic mean of the expressions of the three reference genes (F=0.285, p=0.758) and that they are suitable for calculation of fold change (Supplemental Fig. 2) . HIV significantly increased the expression of COMT (fold change = 1.075; t=3.206, p=0.015; Cohen's d=0.665, effect size r=0.316) while reducing the expression of dopamine receptor D4 (DRD4) (fold change = 0.536; t=6. 430, p=0.0004; d=4.777, r=0.922) , suggesting the involvement of dopaminergic pathway. We observed significant reductions in SYP (fold change = 0.742; t=3.344, p= 0.012; d=2.466, r=0.777) and MAP2 (fold change=0.764; t= 5.050, p=0.0015; d=4.251, r=0.905) compared to control SH-SY5Y neurons, suggesting a HIV-induced synaptic and dendritic damage. The reduced MAP2 expression was ameliorated with concomitant exposure of tolcapone [10 nM], with the expression normalised relative to controls and increased compared to HIV alone (fold change = 0.940; t=4.690, p= 0.009; d=3.837, r=0.887). Tolcapone also normalised the expression of COMT and DRD4 relative to controls and significantly decreased COMT versus HIV alone (fold change = 0.915; t=3.529, p=0.024; d=2.882, r=0.822). The expression of DRD4 was also significantly increased versus HIV alone (fold change = 0.819, t =4.715, p =0.0009; d =3.850, r= 0.887). Finally, tolcapone restored the level of SYP; however, this did not reach statistical significance (fold change = 0.901, t=1.344, p=0.250; d=1.097, r=0.481) (Fig. 1) .
Protein expression changes by immunofluorescence
Immunofluorescence was performed in an attempt to validate the gene expression changes observed for SYP and MAP2 at the protein level. We found a trend of HIV decreasing the intensity of SYP (t =1.192, p=0.299; d=0.973, r=0.438) and MAP2 (t=0.951, p=0.396; d=0.776, r=0 .362) compared to control SY5Y neurons. Concomitant exposure of tolcapone ameliorated the reduced intensity of SYP (t=4.519, p=0.011; d=3.690, r=0.879) and MAP2 (t=1.458, p=0.219; d=1.191, r=0 .512) compared to HIV alone. Interestingly, concomitant exposure to tolcapone and HIV significantly increased the intensity of SYP compared to control (t=2.691, p=0.055; d=2.198, r=0.740) (Fig. 2) . These results suggest that the disturbance in mRNA expression was present at the protein level too.
Discussion
Taken together, our results suggest that tolcapone, a known inhibitor of COMT, confers a protective effect against HIVassociated dendritic and synaptic damage. Consistent with previous findings (Masliah et al. 2004 ), we observed synaptic and cytoskeletal damage associated with HIV, as conferred by the reduction of the expressions of SYP and MAP2. However, this effect was not observed when COMT activity was inhibited with a concomitant exposure of tolcapone at both the gene and protein expression levels. Nevertheless, our results are the first to demonstrate that tolcapone may be protective against HIV-associated neurodegeneration through the inhibition of COMT. Restriction of COMT enzymatic activity would act to preserve the more optimal downstream cortical dopamine level needed for normal cognitive performance. We induced HIV-mediated neurodegeneration in vitro in our SH-SY5Y-differentiated neurons as shown by the decreased mRNA expression of neuronal markers SYP and MAP2 in cultures exposed to a brain-derived, neurotropic HIV strain. The mRNA expression of COMT was also upregulated, while DRD4 was downregulated following HIV exposure, indicating possible involvement of dopaminergic system. Based on the inverted U curve model, inhibiting COMT in our SH-SY5Y model potentially altered the level of dopamine, therefore affecting the expression of this dopamine receptor. Specifically for MAP2 expression changes following the inhibition of COMT, it was previously reported that D1-like dopamine receptor may alter the phosphorylation state of MAP2 protein, therefore changing the stability of dendritic cytoskeleton. Our findings suggest a possible involvement of DRD4 (D2-like dopamine receptor) in regulating MAP2 in an opposite manner compared to D1-like receptors. Fig. 1 mRNA expression We further examined the protein expression of SYP and MAP2 in order to validate the findings of altered mRNA expression of the neuronal markers in SY5Y neuronal culture. Quantitative immunofluorescence staining intensity revealed changes of SYP and MAP2 protein expression consistent with that of mRNA expression when exposed to HIV as well as HIV and tolcapone concurrently. We considered that the fragmentation of DNA may have influenced the DAPI signal correction for HIV cultures versus controls; however, the observed increase in SYP and MAP2 is highly consistent with the qPCR results, therefore supporting its reliability. These findings indicate that COMT dysregulation may be a possible mechanism that leads to HIV-associated cognitive deficit as portrayed in the inverted U-shaped curve (Goldman-Rakic et al. 2000) . Furthermore, HIV-associated neurodegeneration induced by dysregulation of COMT may be restored via the treatment of tolcapone, and appears to occur at the mRNA and protein levels. It is noteworthy for our experiments that the neurotoxic effects we observed for HIV as shown by reduced expression levels of SYP and MAP2 in our cultures may have been elicited via the release of soluble factors from MDMs exposed to the whole virus, such as pro-inflammatory cytokines or alternatively by free viral proteins present in the supernatant. Likewise, our observed neuroprotective effect of tolcapone on HIV-associated neurotoxicity may have also been achieved through attenuating effects of cytokines or viral proteins in the supernatants. Therefore, further mechanistic work is warranted to assess tolcapone's ability to prevent neurotoxicity elicited by individual HIV viral proteins, including gp120, gp41, Tat, Nef and Vpr (Adamson et al. 1996; Brenneman et al. 1988; Jones et al. 2007; Kaul et al. 2001; King et al. 2006; Mordelet et al. 2004; Tunbridge et al. 2006) .
Tolcapone is a US Food and Drug Administration (FDA)-approved compound and is widely used in the treatment of Parkinson's disease (PD). Given its already known pharmacokinetics and availability on the market since 1997, tolcapone may be favoured compared to other COMT inhibitors and substances in the potential therapeutic development for HAND (Mocchetti et al. 2012) . Despite its potential liver toxicity, tolcapone has been found to be efficient in the treatment of PD due to its ability to cross the blood-brain barrier (BBB) and reach the brain while liver injury could be minimised via liver function monitoring (Gottwald et al. 1997) . This is also important in the context of targeting HIV-associated neurodegeneration in the CNS, which may be a significant contributor to HIV-associated neurocognitive impairment.
Further study needs to be conducted to validate the potential therapeutic effects of tolcapone against different strains of HIV and in primary neuronal cultures, which closely represent the microenvironment in the brain as compared to the current model of SH-SY5Y neurons. Moreover, it is important to conduct a larger scale experiment focusing on these synaptic and dendritic markers in order to overcome the sample size limitation in the current study. More importantly, it will be crucial to investigate the effect of other COMT inhibitors such as entacapone in order to validate the current findings and determine if tolcapone is a suitable adjunctive therapy with ARVs in the treatment of HIV and HIV-associated neurodegeneration.
Tolcapone is known to exhibit different outcomes in PFC function dependent on COMT genotype. While Val/Val individuals who are believed to have suboptimal level of cortical dopamine may benefit from the treatment of tolcapone, Met/ Met individuals who presumably have near optimal baseline level of cortical dopamine are found to deteriorate with tolcapone (Bitsios and Roussos 2011) . While the current study did not investigate the genotype of SH-SY5Y, it is important for future studies to determine the effect of tolcapone treatment towards neurotoxicity across different genotype variants in vitro. This could be achieved by transfecting SH-SY5Y neurons with Met/Met or Val/Val COMT variant in order to generate two distinct populations of cultures reflecting the two genotypes via novel and elegant genome editing techniques such as TALEN or CRISPR.
In conclusion, our findings demonstrated that in vitro, inhibition of COMT ameliorates HIV-associated neurodegenerative changes that resulted in the decreased expression of the structural and synaptic components MAP2 and SYP. As HIVassociated neurodegeneration is a likely contributor to HAND, inhibition of COMT may represent a potential strategy for attenuating or preventing some of the symptoms of HAND.
